Syntara is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need.
We are targeting extracellular matrix dysfunction with our world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.
Our experienced team of scientists is focusing on correcting extracellular matrix (ECM) dysfunction. The ECM is a crucial component of the cell microenvironment, both under normal as well as fibrotic and inflammatory-driven disease states. By developing effective inhibitors of the key enzymes involved, we can correct dysfunction within the ECM, leading to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
Syntara’s lead candidate, SNT-5505, is currently being evaluated in a Phase 2 multinational study targeting myelofibrosis, a blood cancer characterised by scarring (fibrosis) of the bone marrow. A further clinical study in a second haematological malignancy, myelodysplastic syndrome, will be initiated shortly.
Our clinical-stage pipeline also includes trials in skin fibrosis (scar prevention and modification) and neuroinflammatory-driven diseases such as Parkinson’s (joint collaboration with Parkinson’s UK).
Syntara’s expertise is founded in a deep understanding of the chemistry and biology of oxidase enzymes, key drivers of fibrosis and inflammation. Our clinical pipeline is bolstered by programs targeting specific amine oxidase family members implicated in a host of chronic diseases, including pulmonary fibrosis, NASH and cardiac fibrosis.